Remove 2030 Remove Compounding Remove Vaccines
article thumbnail

Cell and gene therapy: The vital role of logistics

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? The projected growth of the cell and gene therapy market GlobalData estimates that the cell and gene therapy market will achieve global sales of $76.03bn by 2030, up from $5.88bn in 2023, with a compound annual growth rate (CAGR) of 44% over the seven years analysed.

article thumbnail

Respiratory syncytial virus prophylactic market to surpass $6 bn across 8MM in 2030

Express Pharma

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM*) is forecast to grow at a compound annual growth rate (CAGR) of 26.7 billion in 2030, with the pediatric and adult segments accounting for $2.2 Six more products in late-stage development have potential to launch by 2030.

Vaccines 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Single-use bioreactor market to witness favourable expansion to 2030

European Pharmaceutical Review

A report by Azoth Analytics expects that globally, the single-use technology rocking bioreactors market will grow at a compound annual growth rate (CAGR) of 3.9 percent between 2025 and 2030. The report noted that last year, the cell culture sector held approximately 60 percent of the single-use technology rocking bioreactors market.

article thumbnail

The Path to Cervical Cancer Eradication: Overcoming Barriers to HPV Vaccination

Pharmacy Times

The introduction of the human papillomavirus (HPV) vaccine marked a major turning point, contributing to nearly a 50% reduction in incidence rates and a 70% decrease in mortality since the 1950s.

article thumbnail

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025.

article thumbnail

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

PharmaTech

million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L. Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L.

Dosage 59
article thumbnail

Pharmacies Need Strategies to Improve Health Care Access

Pharmacy Times

The Healthy People 2030 initiative addresses structural health care inequalities and implements programs to ameliorate SDOH. Healthy People 2030. Each unique set of economic, educational, social, and environmental circumstances significantly affects their quality of life and health. REFERENCES 1. Social determinants of health.